Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year - 24 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- 3The Significance of a Land Lawyer for Your Business
- 4Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
- 5Surprising links between autism, Alzheimer’s could change how we treat both
- Which camera do you believe is great for first-time clients? !
- Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- The Most Rousing Ladies Business visionaries of Today
- 6 Arranging Administrations to Change Your Open air Space
- Vote In favor of Your Favored IT Administration
- Dental, Vision, and Hearing Inclusion in Senior Protection.
